| scholarly article | Q13442814 |
| P356 | DOI | 10.1017/S1047951116002237 |
| P698 | PubMed publication ID | 28084961 |
| P50 | author | Shubhayan Sanatani | Q43748749 |
| P2093 | author name string | Thomas M Roston | |
| Taylor C Cunningham | |||
| P2860 | cites work | A cardiac arrhythmia syndrome caused by loss of ankyrin-B function | Q24295030 |
| Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death | Q24300356 | ||
| Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human | Q24307681 | ||
| Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans | Q24608179 | ||
| Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia | Q28201561 | ||
| A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel | Q28204838 | ||
| Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia | Q28279395 | ||
| Catecholaminergic polymorphic ventricular tachycardia | Q28287523 | ||
| Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis | Q28308142 | ||
| New exome data question the pathogenicity of genetic variants previously associated with catecholaminergic polymorphic ventricular tachycardia | Q30666264 | ||
| Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts | Q33145152 | ||
| Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. | Q33147854 | ||
| Screening for ryanodine receptor type 2 mutations in families with effort-induced polymorphic ventricular arrhythmias and sudden death: early diagnosis of asymptomatic carriers. | Q33147876 | ||
| A missense mutation in CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel | Q33151465 | ||
| Pathogenesis of unexplained drowning: new insights from a molecular autopsy | Q33152673 | ||
| Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia | Q33157356 | ||
| Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia | Q33159716 | ||
| Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments | Q33160416 | ||
| The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands | Q33161041 | ||
| Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives | Q33161522 | ||
| Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. | Q33162208 | ||
| Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. | Q33163389 | ||
| Early repolarization is associated with symptoms in patients with type 1 and type 2 long QT syndrome | Q33164334 | ||
| Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry | Q33165339 | ||
| Physical and Psychological Consequences of Left Cardiac Sympathetic Denervation in Long-QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia | Q33166057 | ||
| Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients | Q33173888 | ||
| The role of mutant protein level in autosomal recessive catecholamine dependent polymorphic ventricular tachycardia (CPVT2). | Q33919062 | ||
| Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. | Q34160930 | ||
| Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia | Q34629553 | ||
| Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function | Q35279976 | ||
| Thoracoscopic Left Cardiac Sympathetic Denervation for a Patient with Catecholaminergic Polymorphic Ventricular Tachycardia and Recurrent Implantable Cardioverter-Defibrillator Shocks. | Q35720196 | ||
| Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: A systematic review and meta-analysis of inappropriate shocks and complications | Q35781029 | ||
| Psychological functioning and disease-related quality of life in pediatric patients with an implantable cardioverter defibrillator | Q35851697 | ||
| A mechanism for sudden infant death syndrome (SIDS): stress-induced leak via ryanodine receptors | Q35904783 | ||
| Loss of luminal Ca2+ activation in the cardiac ryanodine receptor is associated with ventricular fibrillation and sudden death | Q36156989 | ||
| Assessing the knowledge of sudden unexpected death in the young among Canadian medical students and recent graduates: a cross-sectional study | Q36496344 | ||
| In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia. | Q36667578 | ||
| Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia | Q36853107 | ||
| Catecholaminergic polymorphic ventricular tachycardia: A paradigm to understand mechanisms of arrhythmias associated to impaired Ca(2+) regulation | Q37625277 | ||
| The structural biology of ryanodine receptors | Q37904888 | ||
| Gene therapy clinical trials worldwide to 2012 - an update. | Q38077166 | ||
| Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate | Q38106029 | ||
| HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. | Q38134931 | ||
| Cardiac sympathetic denervation to prevent life-threatening arrhythmias | Q38194843 | ||
| Sudden cardiac death in neuromuscular disorders | Q38628961 | ||
| Early repolarization of surface ECG predicts fatal ventricular arrhythmias in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy and symptomatic ventricular arrhythmias | Q38987868 | ||
| Ryanodine receptor mutations presenting as idiopathic ventricular fibrillation: a report on two novel familial compound mutations, c.6224T>C and c.13781A>G, with the clinical presentation of idiopathic ventricular fibrillation | Q39172567 | ||
| Implantable cardioverter-defibrillator explantation for overdiagnosed or overtreated congenital long QT syndrome | Q40866214 | ||
| Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia | Q41268618 | ||
| Single delivery of an adeno-associated viral construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age. | Q42215203 | ||
| The human CASQ2 mutation K206N is associated with hyperglycosylation and altered cellular calcium handling | Q42469020 | ||
| Genetic background of catecholaminergic polymorphic ventricular tachycardia in Japan | Q44293793 | ||
| Triadin overexpression stimulates excitation-contraction coupling and increases predisposition to cellular arrhythmia in cardiac myocytes | Q44461573 | ||
| Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations | Q45273441 | ||
| The direct actions of flecainide on the human cardiac ryanodine receptor: keeping open the debate on the mechanism of action of local anesthetics in CPVT. | Q47723591 | ||
| Gain-of-function mutation of the SCN5A gene causes exercise-induced polymorphic ventricular arrhythmias | Q48550349 | ||
| Response to Letters Regarding Article, "Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation". | Q48747281 | ||
| Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade | Q59200864 | ||
| Delay to diagnosis amongst patients with catecholaminergic polymorphic ventricular tachycardia | Q61632866 | ||
| Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia | Q62105551 | ||
| Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia | Q78390804 | ||
| Molecular pathogenesis of catecholaminergic polymorphic ventricular tachycardia: sex matters! | Q79833038 | ||
| Prophylactic left thoracic sympathectomy to prevent electrical storms in CPVT patients needing ICD placement | Q83816623 | ||
| Importance of ventricular tachycardia storms not terminated by implantable cardioverter defibrillators shocks in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia | Q83821934 | ||
| P433 | issue | S1 | |
| P921 | main subject | catecholaminergic polymorphic ventricular tachycardia | Q1649897 |
| P304 | page(s) | S49-S56 | |
| P577 | publication date | 2017-01-01 | |
| P1433 | published in | Cardiology in the Young | Q2041555 |
| P1476 | title | Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia | |
| P478 | volume | 27 |
Search more.